• 1
    Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics. 2006; 117: e711e716.
  • 2
    Steinbach WJ, Loeffler J, Stevens D. Aspergillosis. In: WingardJR, AnaissieE, editors. Fungal Infections in the Immunocompromised Patient. New York: Taylor & Francis; 2005: 257294.
  • 3
    Wingard JR, Leather H. A new era of antifungal therapy. Biol Blood Marrow Transplant. 2004; 10: 7390.
  • 4
    Wingard JR, Nichols WG, McDonald GB. Supportive care. Hematology Am Soc Hematol Educ Program. 2004; 372389.
  • 5
    Steinbach WJ. Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies. Curr Drug Targets Infect Disord. 2005; 5: 203210.
  • 6
    Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol. 2005; 43( suppl 1): S4958.
  • 7
    Stynen D, Goris A, Sarfati J, Latge JP. A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. J Clin Microbiol. 1995; 33: 497500.
  • 8
    Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002; 34: 714.
  • 9
    Wheat LJ. Antigen detection, serology, and molecular diagnosis of invasive mycoses in the immunocompromised host. Transpl Infect Dis. 2006; 8: 128139.
  • 10
    Anaissie E. Trial design for mould-active agents: time to break the mold. Aspergillosis in neutropenic adults. Clin Infect Dis. 2007; 44: 12981306.
  • 11
    Anaissie EJ. Trial design for mold active agents: time to brewak the mold—aspergillosis in neutropenic patients. Clin Infect Dis. 2007; 44: 12981306.
  • 12
    Miceli MH, Maertens JA, Grazziutti ML, et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description and clinical and research implications. Cancer. 2007; 110: 112120.
  • 13
    Almyroudis NG, Kontoyiannis DP, Sepkowitz KA, DePauw BE, Walsh TJ, Segal BH. Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. Clin Infect Dis. 2006; 43: 14491455.
  • 14
    Chmura Kraemer H, Periyakoil VS, Noda A. Kappa coefficients in medical research. Stat Med. 2002; 21: 21092129.
  • 15
    Boutboul F, Alberti C, Leblanc T, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis. 2002; 34: 939943.
  • 16
    Herbrecht R, Johnson E, Barrette M, et al. Longitudinal assessment of galactomannan antigenemia and relationship with outcome in invasive aspergillosis. In: Advances Against Aspergillosis. San Francisco; Mycopathologia. 2005; 159: 315317.